GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Phase 2

Active, not recruiting

Conditions: Alzheimer's Disease

Interventions: Drug: GSK4527226
Other: Placebo

First Posted Date: 2023-10-12

Last Posted Date: 2025-04-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 367

Registration Number: NCT06079190

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Phase 1

Recruiting

Conditions: Neoplasms

Interventions: Drug: GSK4524101
Drug: Niraparib

First Posted Date: 2023-10-11

Last Posted Date: 2024-04-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 135

Registration Number: NCT06077877

Locations: 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada

Concentration-QT Study of Paroxetine in Healthy Adults

Phase 1

Completed

Conditions: Anxiety Disorders

Interventions: Drug: Paroxetine

First Posted Date: 2023-10-04

Last Posted Date: 2024-12-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 38

Registration Number: NCT06065735

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Phase 2

Recruiting

Conditions: Neoplasms, Head and Neck

Interventions: Drug: Dostarlimab
Drug: Belrestotug
Drug: GSK4381562
Drug: Nelistotug

First Posted Date: 2023-10-02

Last Posted Date: 2024-11-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 360

Registration Number: NCT06062420

Locations: 🇹🇷
GSK Investigational Site, Izmir, Turkey

A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants

Phase 1

Recruiting

Conditions: Hepatitis B

Interventions: Drug: Bepirovirsen

First Posted Date: 2023-09-28

Last Posted Date: 2024-04-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 160

Registration Number: NCT06058390

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

Phase 4

Recruiting

Conditions: Asthma

Interventions: Drug: Mepolizumab
Other: Spirometry

First Posted Date: 2023-09-18

Last Posted Date: 2025-02-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 336

Registration Number: NCT06041386

Locations: 🇪🇸
GSK Investigational Site, Valencia, Spain

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks

Phase 3

Completed

Conditions: Gastroenteritis

Interventions: Combination Product: GSK's liquid oral live attenuated HRV
Combination Product: PCV-free liquid formulation of GSK's oral live attenuated HRV